Related Articles
Combining selective inhibitors of nuclear export (SINEs) with chimeric antigen receptor (CAR) T cells for CD19‑positive malignancies
Efficacy and safety of humanized CD19 CAR‑T as a salvage therapy for recurrent CNSL of B‑ALL following murine CD19 CAR‑T cell therapy
Dual specific CD19/CD22‑targeted chimeric antigen receptor T‑cell therapy for refractory diffuse large B‑cell lymphoma: A case report
CD19/CD22 bispecific chimeric antigen receptor‑NK‑92 cells are developed and evaluated
Effect and changes in PD‑1 expression of CD19 CAR‑T cells from T cells highly expressing PD‑1 combined with reduced‑dose PD‑1 inhibitor